Senores Pharmaceuticals

Senores Pharmaceuticals delivered a stellar Q4 FY26, with consolidated revenue of 190 croresCurrent reported value: 190 crores. No comparable prior figure is available in the source record. (up 66% YoY) and EBITDA of 62 croresCurrent reported value: 62 crores. No comparable prior figure is available in the source record. (up 3x YoY), driven by 83%Current 83%. Reported change: +83% YoY. growth in regulated markets. For the full year, revenue hit 663 croresCurrent reported value: 663 crores. No comparable prior figure is available in the source record. (up 62% YoY) and PAT reached 122 croresCurrent reported value: 122 crores. No comparable prior figure is available in the source record. (up 108Current reported value: 108. No comparable prior figure is available in the source record.% YoY), surpassing guidance. The approved ANDA portfolio more than doubled to 51Current 51. Reported change: +29 YoY., with 30 launches expected over 6-8 quarters. Management guided FY27Current reported value: 27. No comparable prior figure is available in the source record. revenue growth of 30-40% and PAT growth of 50-60%, supported by a robust pipeline and the Upnar acquisition (expected 80-100 crores revenue). Key risks include geopolitical uncertainties and inflationary pressures in the US, which management cited for conservative guidance.